Study Results Find Interaction Between Fedratinib and a Strong Inhibitor of CYP3A4
Fedratinib, a selective inhibitor of JAK2, was approved in 2019 by the US FDA for the treatment of certain groups of patients with myelofibrosis.
Diagnosis & Disease Information
Polypharmacy Increases Risk of Post Chemotherapy Inpatient Hospitalization for Older Patients
Patients with cancer aged 65 and older are likely to be taking 5 or more medications before treatment with IV chemotherapy, which can complicate posttreatment care.
Rituximab-Associated Colitis Is Typically Mild, Treated With Supportive Care
A retrospective study assessed the severity of gastrointestinal toxicity in patients treated with rituximab and evaluated various management approaches.
Frequency of Chemotherapy, Medication Desensitization
How often should a patient be desensitized to medications?
Significance of Amino Acid Solution With Lutetium Lu 177 Dotatate
What is the importance of the amino acid solution given before lutetium Lu 177 dotatate? Which is the difference between a specially compounded solution and a standard solution?
Patients’ Satisfaction With Chemotherapy Influences Health-Related Quality of Life in Advanced Thoracic Cancer
Dutch researchers sought to determine the association between satisfaction with treatment and HRQoL scores among patients with locally advanced or metastatic thoracic cancer receiving pemetrexed.
Substitute for Lidocaine
What options are available to minimize the pain associated with goserelin injections?
Drug-Drug Interaction Between Capecitabine and PPIs Reduces Survival in GI Cancers
Drug-drug interaction between capecitabine and common heartburn medications has a negative effect on progression-free survival and overall survival in patients with GI cancer.
Combination of Gemcitabine and New CHK1 Inhibitor Is Effective in Soft Tissue Sarcomas
In a phase 1 clinical trial, the combination produces a significant and long-lasting response in patients with advanced disease including metastases to the peritoneum and lung.
PPIs Negatively Impact Outcomes of Patients Treated With Capecitabine
Because gastric acid suppressants, such as proton pump inhibitors, affect the absorption of some oral cancer medications, researchers sought to determine if proton pump inhibitors impair capecitabine efficacy.
- Loading...
Loading...
Next post in Gastrointestinal Cancer
Loading... 
Loading...